Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

10.5K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
10.5K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

3.1K
3.1K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

12.2K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
12.2K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

6.6K
6.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

5.1K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.8K
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Expert opinion on burning questions in cancer myeloid cell biology.

Journal for immunotherapy of cancer·2026
Same author

A ribonucleotide carbohydrate system (iRNC) enhances antigen presentation and controls glioblastoma.

Theranostics·2026
Same author

CCL3 is produced by aged neutrophils across cancers and promotes tumor growth.

Cancer cell·2026
Same author

Positioning and reversible suppression of CCR7<sup>+</sup> dendritic cells in perivascular tumor niches shape cancer immunity.

Immunity·2025
Same author

Targeting myeloid cell polarization to prevent GBM recurrence.

Molecular therapy : the journal of the American Society of Gene Therapy·2025
Same author

From complexity to consensus: A roadmap for neutrophil classification.

Immunity·2025

Related Experiment Video

Updated: Apr 18, 2026

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues
07:17

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Published on: August 23, 2024

2.1K

Common TLR5 mutations control cancer progression.

Christina Pfirschke1, Christopher Garris1, Mikael J Pittet1

  • 1Center for Systems Biology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.

Cancer Cell
|January 14, 2015
PubMed
Summary

Toll-like receptor 5 (TLR5) signaling deficiency alters gut microbiota interactions, impacting inflammatory pathways. This deregulation can influence the progression of extraintestinal cancers in susceptible individuals.

More Related Videos

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

25.3K
Experimental Metastasis and CTL Adoptive Transfer Immunotherapy Mouse Model
08:06

Experimental Metastasis and CTL Adoptive Transfer Immunotherapy Mouse Model

Published on: November 26, 2010

20.4K

Related Experiment Videos

Last Updated: Apr 18, 2026

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues
07:17

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Published on: August 23, 2024

2.1K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

25.3K
Experimental Metastasis and CTL Adoptive Transfer Immunotherapy Mouse Model
08:06

Experimental Metastasis and CTL Adoptive Transfer Immunotherapy Mouse Model

Published on: November 26, 2010

20.4K

Area of Science:

  • Oncology
  • Immunology
  • Microbiology

Background:

  • Tumor-associated inflammation mechanisms remain poorly understood.
  • The role of microbial interactions in cancer development is an active area of research.

Purpose of the Study:

  • To investigate the impact of Toll-like receptor 5 (TLR5) signaling deficiency on tumor-associated inflammation and cancer progression.
  • To explore the interplay between commensal microbiota and inflammatory deregulation in the context of cancer.

Main Methods:

  • Analysis of TLR5 signaling pathways in cancer models.
  • Investigation of host-microbiota interactions in the presence of TLR5 deficiency.
  • Assessment of inflammatory cascades and their effect on tumor growth.

Main Results:

  • TLR5 signaling deficiency, present in approximately 10% of the population, alters host-microbiota interactions.
  • This deficiency deregulates a cascade of inflammatory events.
  • These inflammatory changes can either suppress or accelerate extraintestinal cancers.

Conclusions:

  • TLR5 signaling is a critical regulator of inflammation in the context of gut microbiota.
  • Dysregulation of TLR5 signaling contributes to variable cancer outcomes.
  • Targeting TLR5 or microbiota interactions may offer therapeutic strategies for extraintestinal cancers.